Ji Patrick Xiang, Pickel Lauren, Berger Alan R, Sivachandran Nirojini
Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Toronto Retina Institute, Toronto, ON, Canada.
Case Rep Ophthalmol. 2025 Feb 7;16(1):155-162. doi: 10.1159/000543971. eCollection 2025 Jan-Dec.
This case report describes a finding of dramatic improvement in drusen volume and visual acuity in a 73-year-old patient diagnosed with dry age-related macular degeneration (AMD) undergoing daily home photobiomodulation alongside AREDS-2 supplements.
This is a retrospective review of a case presentation from 2023 to 2024. After 8 months of continuous home photobiomodulation, the patient's visual acuity improved from 20/30 to 20/20 in the left eye while the right eye stabilized at 20/25. The outer retina was preserved without signs of geographic atrophy, with a robust reduction in the total number and volume of drusen in both eyes, left greater than right, as shown with optical coherence tomography macular cross-sectional scans.
These findings support that photobiomodulation has the potential to improve the management of dry AMD and the overall quality of life, consistent with phase III clinical trials. Future studies are warranted to further establish optimized protocols for broader clinical implementation.
本病例报告描述了一名73岁被诊断为干性年龄相关性黄斑变性(AMD)的患者,在每日在家进行光生物调节治疗并服用年龄相关性眼病研究2(AREDS-2)补充剂的情况下,其玻璃膜疣体积和视力得到显著改善。
这是对2023年至2024年病例报告的回顾性研究。经过8个月的持续在家光生物调节治疗,患者左眼视力从20/30提高到20/20,右眼稳定在20/25。光学相干断层扫描黄斑横断面扫描显示,双眼视网膜外层得以保留,无地图样萎缩迹象,玻璃膜疣总数和体积大幅减少,左眼减少幅度大于右眼。
这些发现支持光生物调节治疗有改善干性AMD管理和整体生活质量的潜力,这与III期临床试验结果一致。未来有必要开展进一步研究,以确定更优化的方案,以便更广泛地应用于临床。